Immunological Risk Factors in Recurrent Pregnancy Loss: Guidelines Versus Current State of the Art
Open accessThe DOI matches its Crossref record; 198 of the 198 references it cites were found in a registry or an index.
Abstract
Around 1–5% of all couples experience recurrent pregnancy loss (RPL). Established risk factors include anatomical, genetic, endocrine, and hemostatic alterations. With around 50% of idiopathic cases, immunological risk factors are getting into the scientific focus, however international guidelines hardly take them into account. Within this review, the current state of immunological risk factors in RPL in international guidelines of the European Society of Reproduction and Embryology (ESHRE), American Society of Reproductive Medicine (ASRM), German/Austrian/Swiss Society of Obstetrics and Gynecology (DGGG/OEGGG/SGGG) and the Royal College of Obstetricians and Gynecologists (RCOG) are evaluated. Special attention was drawn to recommendations in the guidelines regarding diagnostic factors such as autoantibodies, natural killer cells, regulatory T cells, dendritic cells, plasma cells, and human leukocyte antigen system (HLA)-sharing as well as treatment options such as corticosteroids, intralipids, intravenous immunoglobulins, aspirin and heparin in RPL. Finally, the current state of the art focusing on both diagnostic and therapeutic options was summarized.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“However, the significance of increased peripheral NK cells remains debatable, 101 as they do not appear to reflect the levels in the endometrium, 102 show an intracycle, hormonal and ethnic variability, 103 and appear not to predict subsequent miscarriage in a population of women with recurrent miscarriage.104”
From Recurrent MiscarriageGreen‐top Guideline No. 17 (2023) · cites this paper as [101]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MIYAKIS, S., LOCKSHIN, M. D., ATSUMI, T., BRANCH, D. W., BREY, R. L., CERVERA, R., DERKSEN, R. H. W. M., DE GROOT, P. G., KOIKE, T., MERONI, P. L., et al. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01753.x · Cited by 7,203 · cited 1×
“, 2 pregnancy losses or antibody titres in the lower range) (Table 2) [42].”
BackgroundPark, J.-H., Adoro, S., Guinter, T., Erman, B., Alag, A. S., Catalfamo, M., Kimura, M. Y., Cui, Y., Lucas, P. J., Gress, R. E., et al. (2010) · Nature Immunology · doi:10.1038/ni.1840 · Cited by 5,835
Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., & Toda, M. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.3.1151 · Cited by 5,608
Sakaguchi, S. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141122 · Cited by 3,306
Stagnaro-Green, A., Abalovich, M., Alexander, E., Azizi, F., Mestman, J., Negro, R., Nixon, A., Pearce, E. N., Soldin, O. P., Sullivan, S., et al. (2011) · Thyroid · doi:10.1089/thy.2011.0087 · Cited by 2,942
Alexander, E. K., Pearce, E. N., Brent, G. A., Brown, R. S., Chen, H., Dosiou, C., Grobman, W. A., Laurberg, P., Lazarus, J. H., Mandel, S. J., et al. (2017) · Thyroid® · doi:10.1089/thy.2016.0457 · Cited by 2,731 · cited 1×
“Thyroid autoimmunity is associated with adverse pregnancy outcomes such as preterm delivery and pregnancy loss, as well as infertility [43].”
BackgroundDecidual NK cells regulate key developmental processes at the human fetal-maternal interface
Hanna, J., Goldman-Wohl, D., Hamani, Y., Avraham, I., Greenfield, C., Natanson-Yaron, S., Prus, D., Cohen-Daniel, L., Arnon, T. I., Manaster, I., et al. (2006) · Nature Medicine · doi:10.1038/nm1452 · Cited by 1,681
EULAR recommendations for the management of antiphospholipid syndrome in adults
Tektonidou, M. G., Andreoli, L., Limper, M., Amoura, Z., Cervera, R., Costedoat-Chalumeau, N., Cuadrado, M. J., Dörner, T., Ferrer-Oliveras, R., Hambly, K., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215213 · Cited by 1,318
Evaluation and treatment of recurrent pregnancy loss: a committee opinion
(2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2012.06.048 · Cited by 1,308
Decisions About Dendritic Cells: Past, Present, and Future
Steinman, R. M. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-100311-102839 · Cited by 1,274 · cited 4×
“If TSH levels are >2.5 mU/L, T3, T4 and thyroid autoantibody concentrations should be determined A ll oi m m un e R is k Fa ct or s Im m un e C el ls Controversial scientific evidence for dendritic cells or regulatory T-cells Most data available for uNKs, is controversial and testing can only be recommended within stu…”
BackgroundInfluential
Cited by
Items 101–123 of 123
Lu, F., Li, P., & Yang, P. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2025.1738040
Panov, V. V., & Duka, Y. M. (2025) · UKRAINIAN JOURNAL HEALTH OF WOMAN · doi:10.15574/hw.2025.4(179).2838
Gayete-Lafuente, S., Guijarro-Baude, L., Choong, E., Barad, D. H., & Gleicher, N. (2026) · American Journal of Reproductive Immunology · doi:10.1111/aji.70217
Andersen, L. H. J., Hare, K. J., Palmø, J., Salby, S. B., Eriksen, J. O., Gerlach, M. K., Macklon, N. S., Martinez, R. S., Dai, Y., Sandelin, A., et al. (2026) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2026.104876 · Cited by 1
Success pregnancy rate after use of intralipid in recurrent pregnancy loss
Abdulaal, N., Boudjelal, Y., Ijz, N., & Alamro, M. (2026) · doi:10.65759/q601bv90
Qiu, W., Wang, S., Huang, Y., Xu, N., Yang, J., & Wu, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1753732
“Globally, an estimated 23 million miscarriages occur each year, with the overall risk in clinically con fi rmed pregnancies reaching 15.3%, imposing a signi fi cant physiological, psychological, and economic burden on women and their families worldwide (5, 6).”
InfluentialGhanem, L., & Ali, T. (2026) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-026-09147-5
“RPL remains a profound clinical challenge, with many cases idiopathic [11].”
Li, Y. S., Zhang, W., Chen, Q., Wang, X., Xie, T., Cheng, T., & Li, X. (2026) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-026-09136-8
“Moreover, patients with URPL exhibit a high rate of embryo loss ranging from 40% to 80% following their future pregnancy [4].”
InfluentialThyroid and nuclear autoantibody profiling in recurrent pregnancy loss
Ali, G. M., Al-alouci, M. M. H., & Obeid, R. Z. (2026) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.22.4.2026.1728
Early Pregnancy and Miscarriage
von Steinburg, S. P. (2026) · Springer eBooks · doi:10.1007/978-3-662-70578-0_2
Coo, M. V., Alentajan-Aleta, L. T., Pepito, S. L., & Silao, J. N. I. (2026) · Philippine journal of allergy, asthma and immunology · doi:10.70552/pjaai.26.1.15979
Song, Z., Jiang, Y., Zhu, Z., Che, Y., Li, S., & Zhao, A. M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1875194
“Although de fi nitions vary internationally, most guidelines de fi ne RPL as two or more consecutive pregnancy losses, whereas others adopt a threshold of three losses while still allowing earlier evaluation in high-risk populations (3 – 5).”
Tokuoka, A., Iida, K., Yamada, M., Ono, M., & Irie, N. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1900874
Immunoglobulins in recurrent pregnancy loss: Emerging biomarkers and therapeutic targets
Kulsum, U., S, P. K. K., Shekar, P. K., Kamala, C., Krishnaswami, N. M. S., Hegde, A., Jayakrishna, L. V., Shivakumaraswamy, M. H., & Prashant, A. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12514-2
“However, it is critical to note that the current guidelines from the American Society for Reproductive Medicine (ASRM) and the European Society of Human Reproduction and Embryology (ESHRE) do not recommend routine IVIG for unexplained RPL due to insufficient high-quality evidence [19, 83].”
Haias, S. T., & Amin, Z. A. (2026) · Zanco Journal of Medical Sciences · doi:10.15218/zjms.2026.032
Attieh, P., Chendab, S., Ghaleb, J., Katrib, N., Ghadieh, H. E., & Dabaj, E. (2026) · Journal of Gynecology Obstetrics and Human Reproduction · doi:10.1016/j.jogoh.2026.103251
Kamala, C., Shekar, P. K., Kulsum, U., Hegde, A., Jayakrishna, L. V., Bhat, D., Shivakumaraswamy, M. H., Prashant, A., & S, P. K. K. (2026) · Immunologic Research · doi:10.1007/s12026-026-09820-z · Cited by 1
“However, current evidence supporting a direct role for IgD in the immunopathogenesis of recurrent pregnancy loss is limited; therefore, this review focuses primarily on immunoglobulin classes for which stronger experimental and clinical evidence is available [ 47].”
InfluentialNadarajan, S., Suresh, A., Roy, D., Muninathan, N., Gopikrishnan, V., Jose, J., & Veetil, A. P. (2026) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2026-0014
“Therapeutic strategies like lymphocyte immunotherapy (LIT), corticosteroids, intralipids, and Intravenous Immunoglobulin (IVIG) have shown variable e ffi cacy in correcting immune imbalances in such patients [6, 7].”
Velikova, T. V., Kokudeva, M., Mihova, A., Angelova, A., & Pencheva, B. (2026) · Pharmacia · doi:10.3897/pharmacia.73.e168168
“Approximately 50% of idiopathic cases of unsuccessful pregnancy may be associated with immunological causes (Vomstein et al. 2021; Guan et al. 2024; Uța et al. 2024).”
Koshak, E. A., Hosam, S. A., Atwah, A. F., Aljedani, R., Aljaied, Y., & Mahmoud, A. G. (2023) · Journal of Fertility Biomarkers · doi:10.14302/issn.2576-2818.jfb-23-4605
Molecular Biomarkers and Pathways in Recurrent Spontaneous Abortion: A Systematic Review.
Moradzadeh, M. K., Azadian, M., Shafie, N., Alavimanesh, S., Alashti, S. K., & Dorri, Z. (2026) · PubMed Central · doi:10.22074/ijfs.2026.2069378.1935
“RSA has a significant impact on both the physical and psychological well-being of the affected individuals, substantially reducing quality of life (4, 5).”
Kofod, L., Waagepetersen, R. P., Christiansen, O. B., & Kesmodel, U. S. (2026) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2026.104983
Yildirim, O., GÜNDOĞDU, H., Abbas-Kabiri, D., Naseri, A., Baharaghdam, S., Chakari-Khiavi, F., Aghapour, A., Miahipour, A., Hakimi, P., Pourlak, T., et al. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-13122-w
Metadata
- Authors
- Vomstein, K., Feil, K., Strobel, L., Aulitzky, A., Hofer-Tollinger, S., Kuon, R.-J., & Toth, B.
- Affiliations
- Innsbruck Medical University (AT)
- Heidelberg University (DE)
- Department of Gynecological Endocrinology and Reproductive Medicine, Medical University Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria
- Corresponding author
- Vomstein, Kilian
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2021-02-20
- Volume
- 10
- Issue
- 4
- Pages
- 869
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC7923780
- OpenAlex
- W3133182888
- Cited by
- 113
- References
- 198
- Citations by year
- 2026: 18 · 2025: 17 · 2024: 28 · 2023: 28 · 2022: 18 · 2021: 4
- FWCI
- 2.00
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Tiroler Wissenschaftsförderung (F.16962/5-2019)
- Austrian Science Fund (33249-B)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Reproductive System and Pregnancy
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Health and Technologies
- Keywords
- recurrent pregnancy loss, immunological risk factors, autoantibodies, natural killer cells, regulatory T cells, dendritic cells, plasma cells, corticosteroids, Intralipid, intravenous immunoglobulin, aspirin, heparin, idiopathic recurrent pregnancy loss
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.